Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BCDA
BioCardia, Inc. Common Stock
stock NASDAQ

At Close
Jul 3, 2025 3:59:30 PM EDT
2.12USD+1.727%(+0.04)3,037,617
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jul 3, 2025 9:28:31 AM EDT
2.09USD+0.288%(+0.01)489,998
After-hours
Jul 3, 2025 4:58:30 PM EDT
2.07USD-2.292%(-0.05)10,691
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 24, 2022
02:30PM EST  BioCardia Shares See Volume; Dawson James Upgrades To Buy Rating, Sets $4 Price Target   Benzinga
Jan 10, 2022
08:00AM EST  BioCardia, Inc.(Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during two investor meetings:   GlobeNewswire Inc
Dec 20, 2021
11:58AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021   Benzinga
06:07AM EST  HC Wainwright & Co. Initiates Coverage On BioCardia with Buy Rating, Announces Price Target of $9   Benzinga
Dec 15, 2021
08:00AM EST  BioCardia Establishes New Manufacturing Facility to Enable Its   GlobeNewswire Inc
Nov 10, 2021
06:38PM EST  BioCardia Q3 EPS $(0.16) Beats $(0.21) Estimate, Sales $821.00K Beat $10.00K Estimate   Benzinga
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Oct 21, 2021
12:11PM EDT  BioCardia Announces First Patient Treated In CardiAMP Cell Therapy Trial For Chronic Myocardial Ischemia   Benzinga
07:30AM EDT  BioCardia Announces First Patient Treated in CardiAMP Cell Therapy   GlobeNewswire Inc
Oct 12, 2021
08:14AM EDT  BioCardia Reports New US Patent For Technology To Enhance Control For Interventional Catheter Based Therapies   Benzinga
08:00AM EDT  BioCardia, Inc.[Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,today announced the issuance of U.S. Patent No: 11,141,568 for Multi Directional Steerable Catheter that further protects theHelix Biotherapeutic Delivery Systemand enhances its biotherapeutic delivery capabilities.   GlobeNewswire Inc
Oct 7, 2021
08:07AM EDT  BioCardia Announces First Cross-Over Patient Treated In CardiAMP Cell Therapy Heart Failure Trial   Benzinga
08:00AM EDT  BioCardia Announces First Cross-Over Patient Treated in CardiAMP   GlobeNewswire Inc
Oct 6, 2021
08:00AM EDT  BioCardia, Inc.(Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases, today announced it will be participating in the A.G.P Biotech & Specialty Pharma Conference taking place virtually on October 13, 2021.   GlobeNewswire Inc
Sep 22, 2021
03:24PM EDT  Why BioCardia's Stock Is Trading Higher Today   Benzinga
09:25AM EDT  Roumell Asset Management Reports In 13D Filing A 5.6% Stake In BioCardia   Benzinga
Sep 10, 2021
08:00AM EDT  CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two   GlobeNewswire Inc
Sep 9, 2021
04:32PM EDT  BioCardia, Inc.(Nasdaq: BCDA), today announced it has recorded a company presentation that will be available on demand at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference. The conference is being heldas a virtual conference on September 13-15, 2021.   GlobeNewswire Inc
Aug 13, 2021
08:00AM EDT  BioCardia, Inc.(Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Companys management team will participate in the following upcoming investor conferences:   GlobeNewswire Inc
Aug 12, 2021
08:26AM EDT  BioCardia Q2 Net Loss $3.5 Mln Vs Loss $3.7 Mln Last Year   RTTNews
08:24AM EDT  BioCardia Q2 EPS $(0.20) Up From $(0.46) YoY   Benzinga
08:00AM EDT  BioCardia, Inc.[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2021 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2021 with the Securities and Exchange Commission.   GlobeNewswire Inc
Aug 4, 2021
08:00AM EDT  BioCardia, Inc.(Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer, Peter Altman, will participate in a fireside chat as well as one on one meetings at the upcoming BTIG Virtual Biotechnology Conference being held August 9-10, 2021.   GlobeNewswire Inc
Jul 15, 2021
08:02AM EDT  BioCardia Announces Japanese Patent On Imaging System For Targeting Cardiac Therapies   Benzinga
Jun 23, 2021
08:12AM EDT  BioCardia Reports Completion Of Fourth Data Safety Monitoring Board Review For Its CardiAMP Cell Therapy Heart Failure Trial; DSMB Indicated No Safety Concerns, Recommended Study Continue As Designed   Benzinga
08:00AM EDT  BioCardia Announces Fourth Positive DSMB Review and Recommendation   GlobeNewswire Inc
Jun 22, 2021
08:03AM EDT  BioCardia To Present CardiAMP Cell Therapy Clinical Trial Data At European Society Of Cardiology Heart Failure 2021   Benzinga
08:00AM EDT  BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at   GlobeNewswire Inc
Jun 21, 2021
08:01AM EDT  BioCardia Reports European Patent Office Decision To Grant Patent On Autologous Cell Therapy Patient Selection Diagnostic Assay   Benzinga
08:00AM EDT  BioCardia Announces European Patent Office Decision to Grant   GlobeNewswire Inc
Jun 14, 2021
08:05AM EDT  BioCardia To be Added to the Russell Microcap Index   Benzinga
Jun 2, 2021
08:00AM EDT  BioCardia, Inc.(Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer Peter Altman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10.   GlobeNewswire Inc
May 13, 2021
08:02AM EDT  BioCardia Q1 EPS $(0.18) Up From $(0.67) YoY   Benzinga
08:00AM EDT  BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today reported financial results for the first quarter of 2021 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2021 with the Securities and Exchange Commission on May 13, 2021.   GlobeNewswire Inc
Apr 26, 2021
08:03AM EDT  BioCardia Signs Agreement With Leading Japanese Biotechnology Company For Catheter Biotherapeutic Delivery Product Candidates; Co. To Receive $500K   Benzinga
08:00AM EDT  BioCardia Signs Agreement with Leading Japanese Biotechnology   GlobeNewswire Inc
Apr 16, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021   Benzinga
08:50AM EDT  Dawson James Downgrades BioCardia to Neutral   Benzinga
Apr 7, 2021
02:39PM EDT  Biocardia Has Received a Decision to Grant European Patent Number Ep3593810 Titled "Methods of Measuring Potential for Therapeutic Potency and Defining Dosages for Autologous Cell Therapies   Benzinga
Mar 30, 2021
08:24AM EDT  BioCardia 2020 Net Loss $15.0 Mln, Revenues $145,000   RTTNews
08:07AM EDT  BioCardia FY2020 Revs $145K Vs $710K YoY   Benzinga
08:00AM EDT  BioCardia, Inc.[Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and recent business highlights. BioCardia has filed its annual 10-K with the Securities and Exchange Commission.   GlobeNewswire Inc
Mar 29, 2021
04:22PM EDT  BioCardia 8-K Shows Co., Lincoln Park Capital Fund Entered Purchase Deal For $20M In Common Shares   Benzinga
Mar 15, 2021
08:00AM EDT  BioCardia, Inc.(Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, announces that CEO Dr. Peter Altman will present at Maxim Groups Inaugural Emerging Growth Virtual Conference to be held March 17-19, 2021.   GlobeNewswire Inc
Feb 23, 2021
08:09AM EST  BioCardia Says Signs Agreement With 'Leading Japanese Pharmaceutical Company' For Catheter Biotherapeutic Delivery Product Candidates   Benzinga
08:00AM EST  BioCardia Signs Agreement With Leading Japanese Pharmaceutical   GlobeNewswire Inc
Feb 17, 2021
08:30AM EST  BioCardia, Inc.[Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,today announced clinical leadership changes.   GlobeNewswire Inc
Feb 2, 2021
08:36AM EST  BioCardia Update on Cell Therapy Product Development And 2021 Milestones   Benzinga
08:30AM EST  BioCardia, Inc.[Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,today provides an update on its cell therapy product development and 2021 milestones.   GlobeNewswire Inc
Jan 11, 2021
08:30AM EST  BioCardia, Inc.[Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,welcomes Krisztina Zsebo, Ph.D., a 31-year veteran of the biotech industry, to its Board of Directors following her election at BioCardias 2020 Annual Meeting of Stockholders in December 2020.   GlobeNewswire Inc
Dec 30, 2020
08:32AM EST  BioCardia Announces That It Was Issued A New U.S. Patent For Its Technology To Enhance Its Cardiac Therapies   Benzinga
08:31AM EST  BioCardia Issues New U.S. Patent For Technology That Enhances Control For Cardiac Therapies   Benzinga
08:30AM EST  BioCardia, Inc.[Nasdaq: BCDA] a leader in the development of comprehensive solutions for cardiovascular regenerative therapies,today announced the issuance of U.S. Patent No: 10,874, 831 for Devices and Methods for Accessing the Vasculature of a Patient that further protects theHelix Biotherapeutic Delivery Systemand enhances its cell therapy delivery capabilities.   GlobeNewswire Inc
Dec 23, 2020
04:15PM EST  Altium Capital Management Reports In 13G Filing A 6.2% Stake In BioCardia   Benzinga
Dec 17, 2020
02:34PM EST  Mid-Afternoon Market Update: Dow Surges 130 Points; SCYNEXIS Shares Slide   Benzinga
12:28PM EST  Mid-Day Market Update: Gold Rises 1.7%; Triterras Shares Plummet   Benzinga
10:30AM EST  Mid-Morning Market Update: Markets Open Higher; Accenture Tops Q1 Estimates   Benzinga
08:40AM EST  BioCardia: DSMB Complete Prespecified Data Review For Phase III Pivotal CardiAMP Heart Failure Trial   RTTNews
08:34AM EST  BioCardia Announces Announces Positive DSMB Review And Recommendation To Continue Phase III Pivotal CardiAMP Heart Failure Study As Designed   Benzinga
08:30AM EST  BioCardia Announces Positive DSMB Review and Recommendation to   GlobeNewswire Inc
08:10AM EST  The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut   Benzinga
Dec 16, 2020
08:44AM EST  BioCardia Announces $10.5 Mln Direct Offering   RTTNews
08:34AM EST  BioCardia, Inc. Announces $10.5M Registered Direct Offering Priced At-The-Market Under Nasdaq Rules   Benzinga
08:30AM EST  BioCardia, Inc. Announces $10.5 Million Registered Direct Offering   GlobeNewswire Inc
07:15AM EST  The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal   Benzinga
Dec 15, 2020
02:32PM EST  Mid-Afternoon Market Update: Dow Surges 370 Points; Mirum Pharmaceuticals Shares Drop   Benzinga
12:26PM EST  Mid-Day Market Update: Crude Oil Rises 1.5%; Apartment Investment and Management Shares Plunge   Benzinga
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
05:49AM EST  BioCardia Announced 1.789M Share Registered Direct Offering Priced @$4.75/Share   Benzinga
01:21AM EST  BioCardia, Inc. Announces $8.5 Million Registered Direct Offering   GlobeNewswire Inc
Dec 14, 2020
03:24PM EST  BioCardia Shares Expected To Resume Trade At 3:27:12 p.m EST   Benzinga
03:23PM EST  BioCardia Reports 1.889M Share Common Stock Offering At $4.75/Share   Benzinga
03:21PM EST  BioCardia, Inc. Announces $8.5 Million Registered Direct Offering   GlobeNewswire Inc
08:10AM EST  BioCardia Says Expects Data Safety Monitoring Board Verbal Feedback For Interim Data From Phase 3 CardiaAMP Heart Failure Trial By End Of Dec. 15, 2020   Benzinga
08:02AM EST  BioCardia Anticipates DSMB Feedback On Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial   Benzinga
08:00AM EST  BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal   GlobeNewswire Inc
Dec 1, 2020
07:05AM EST  BioCardia Highlights Published Study Showing Helix Biotherapeutic Delivery System Used In CardiAMP Phase III Heart Failure Trial Has 'Fewest Adverse Events Among Competitive Delivery Systems'   Benzinga
07:00AM EST  BioCardia Reports Published Study Showing Helix Biotherapeutic   GlobeNewswire Inc
Nov 10, 2020
07:00AM EST  BioCardia, Inc.[NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.   GlobeNewswire Inc
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Oct 30, 2020
08:09AM EDT  The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts   Benzinga
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 26, 2020
07:37AM EDT  BioCardia Highlights Published Peer-Reviewed Initial Data From Biocardia Pivotal Phase 3 Clinical Trial Of Cardiamp   Benzinga
07:30AM EDT  Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months   GlobeNewswire Inc
Sep 29, 2020
08:03AM EDT  BioCardia Issued New Patent For Delivery Of Cardiac Cell Therapy Through Wrist Artery   Benzinga
08:00AM EDT  BioCardia Issued New Patent for Delivery of Cardiac Cell Therapy   GlobeNewswire Inc
Sep 21, 2020
12:00PM EDT  Alliance Global Partners Initiates Coverage On BioCardia with Buy Rating, Announces Price Target of $11.5   Benzinga
Aug 26, 2020
07:00AM EDT  BioCardia to Present at the LD Micro 500 Virtual Conference on   GlobeNewswire Inc
Aug 13, 2020
07:09AM EDT  BioCardia Q2 EPS $(0.46), Up From $(0.77) YoY   Benzinga
07:03AM EDT  BioCardia Q2 Loss/Shr $0.46 Vs Loss $0.77 Last Year   RTTNews
07:00AM EDT  BioCardia, Inc.[NASDAQ: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the second quarter of 2020 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2020 with the Securities and Exchange Commission on August 13, 2020.   GlobeNewswire Inc
Aug 7, 2020
08:00AM EDT  BioCardia, Inc. [NASDAQ:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it will be conducting a mid-year corporate update conference call on Thursday, August 13, 2020 at 8:30AM ET. Following managements formal remarks, there will be a question and answer session.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC